133. Ruoslahti E: Specialization of tumour vasculature. Nat Rev Cancer 2:83, 2002.
134. Muller A, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50, 2001.
135. Yu Y, et al: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators. Nature Med 10:175, 2004.
136. Steeg PS, et al: Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 4:51, 2003.
136A. Cunha GR, et al: Role of stromal microenvironment in carcinogenesis of prostate. Int J Cancer 107:1, 2003.
137. Hogarty MD, Brodeur GM: Gene amplification in human cancers: biological and clinical significance. In Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer, 2nd ed. New York, McGraw-Hill, 2002, p 115–128.
138. Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 4:351, 2003.
139. Herman JG, Baylin S: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042, 2003.
140. Gaudet F, et al: Induction of tumors in mice by genomic hypomethylation. Science 300:489, 2003.
141. Feinberg AP: Genomic imprinting and cancer. In Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer, 2nd ed. New York, McGraw-Hill, 2002, p 43–55.
142. Sorlie T, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418, 2003.
143. Ross ME, et al: Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood, 2003.
144. Hahn WC, Weinberg RA: Rules for making human tumor cells. N Engl J Med 347:1593, 2002.
145. Kinzler KW, Vogelstein B: Colorectal tumors. In Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer, 2nd ed. New York, McGraw-Hill, 2002, p 583.
146. Kunkel TA: Considering the cancer consequences of altered DNA polymerase function. Cancer Cell 3:105, 2003.
147. Fidler IJ: Critical determinants of metastasis. Semin Cancer Biol 12:89, 2002.
148. Tennant R: Chemical carcinogenesis. In Franks LM, Teich NM (eds): An Introduction to the Cellular and Molecular Biology of Cancer, 3rd ed. Oxford, Oxford University Press, 1997, p 106–125.
149. Perera FP: Environment and cancer: who are susceptible? Science 278:1068, 1997.
150. Vineis P, et al: CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 104:650, 2003.
151. Palli D, et al: Biomarkers of dietary intake of micronutrients modulate DNA adduct levels in healthy adults. Carcinogenesis 24:739, 2003.
152. Mortelmans K, Zeiger E: The Ames Salmonella/microsome mutagenicity assay. Mutat Res 455:29, 2000.
153. Staib F, et al: TP53 and liver carcinogenesis. Hum Mutat 21:201, 2003.
154. Mansbach JM, et al: Phenobarbital selectively promotes initiated cells with reduced TGF-receptor levels. Carcinogenesis 17:171, 1996.
155. Montesano R, Hall J: Environmental causes of human cancers. Eur J Cancer 37 (Suppl 8):S67, 2001.
156. Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 3:461, 2002.
157. Talaska G: Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. J Environ Sci Health Part C 21:29, 2003.
158. Preston DL, et al: Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 158:220, 2002.
159. Cleaver JE, Crowley E: UV damage, DNA repair and skin carcinogenesis. Front Biosci 7:1024, 2002.
160. Friedberg RC: Biological responses to DNA damage: a perspective in the new millennium. Cold Spring Harb Symp Quant Biol 65:593, 2000.
161. Williams D: Chernobyl, 15 years later, correlation of clinical, epidemiological and molecular outcomes. Ann Endocrinol 64:72, 2003.
162. Neronova E, Slozina N, Nikiforov A: Chromosome alterations in cleanup workers sampled years after the Chernobyl accident. Radiat Res 160:46, 2003.
163. zur Hausen H: Oncogenic DNA viruses. Oncogene 20:7820, 2001.
164. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342, 2002.
165. Munger K: Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest 20:71, 2002.
166. Helt AM, Galloway DA: Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159, 2003.
167. Munger K, Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 89:213, 2002.
168. zur Hausen H: Cervical cancer: papillomavirus and p53. Nature 393:217, 1998.
169. Dolcetti R, Masucci MG: Epstein-Barr virus: induction and control of cell transformation. J Cell Physiol 196:207, 2003.
170. Bornkamm GW, Hammerschimdt W: Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356:437, 2001.
171. Lam N, Sugden B: CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 15:9, 2003.
172. Thorley-Lawson DA: Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1:75, 2001.
173. Tsao SW, et al: The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 12:473, 2002.
174. Brennan P: Signalling events regulating lymphoid growth and survival. Semin Cancer Biol 11:415, 2001.
175. Thorley-Lawson DA, Gross A: Mechanism of disease: persistence of Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328, 2004.
176. Lindstrom MS, Wiman KG: Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12:381, 2002.
177. Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12:431, 2002.
178. Chen CJ, Chen DS: Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 36:1046, 2002.
179. Wang XW, et al: Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181:43, 2002.
180. Barmak K, et al: Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 308:1, 2003.
181. Mortreux F, Gabet AS, Wattel E: Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 17:26, 2003.
182. Haoudi A, Semmes OJ: The HTLV-1 tax oncoprotein attenuates DNA damage induced G1 arrest and enhances apoptosis in p53 null cells. Virology 305:229, 2003.
183. Covacci A, Rappuoli R: Helicobacter pylori: after the genomes, back to biology. J Exp Med 197:807, 2003.
184. Du MQ, Isaccson PG: Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3:97, 2002.
185. Burnet FM: The concept of immunological surveillance. Prog Exper Tumor Res 13:1, 1970.
186. Dunn GP, et al: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991, 2002.
187. Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346, 2003.
188. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol 22, 2004.
189. Coulie PG, Hanagiri T, Takenoyama M: From tumor antigens to immunotherapy. Int J Clin Oncol 6:163, 2001.
190. Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807, 2003.
191. Boon T, Van den Eynde B: Tumour immunology. Curr Opin Immunol 15:129, 2003.
192. Castelli C, et al: T-cell recognition of melanoma-associated antigens. J Cell Physiol 182:323, 2000.
193. Barker PA, Salehi A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67:705, 2002.
194. Cerwenka A, Lanier LL: Natural killer cells, viruses and cancer. Nat Rev Immunol 1:41, 2001.
195. Latour S, Veillette A: Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev 192:212, 2003.
196. Strand S, Galle PR: Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 4:63, 1998.
197. Hanahan D, Lanzavecchia A, Mihich E: The novel dichotomy of immune interactions with tumors. Cancer Res 63:3005, 2003.
198. Argiles JM, et al: Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 35:405, 2003.
199. Darnell RB, Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543, 2003.
200. Mazzone PJ, Arroliga AC: Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med 9:313, 2003.
201. Hoey RP, et al: The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer 88:567, 2003.
202. Swansbury J: Some difficult choices in cytogenetics. Methods Mol Biol 220:245, 2003.
203. Rowland JM: Molecular genetic diagnosis of pediatric cancer: current and emerging methods. Pediatr Clin North Am 49:1415, 2002.
204. Bayani J, Squire JA: Advances in the detection of chromosomal aberrations using spectral karyotyping. Clin Genet 59:65, 2001.
205. Weiss MM, et al: Comparative genomic hybridisation as a supportive tool in diagnostic pathology. J Clin Pathol 56:522, 2003.
206. Louis DN, Pomeroy SL, Cairncross JG: Focus on central nervous system neoplasia. Cancer Cell 1:125, 2002.
207. Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 2:210, 2002.
208. Lakhani SR, Ashworth A: Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1:151, 2001.
209. Riggins GJ, Morin PJ: Gene expression profiling in cancer. In Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancers, 2nd ed. New York, McGraw-Hill, 2002, p 131– 141.
210. Benes V, Muckenthaler M: Standardization of protocols in cDNA microarray analysis. Trends Biochem Sci 28:244, 2003.
211. Ferrando AA, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75, 2002.
212. Nutt CL, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602, 2003.
213. Ramaswamy S, et al: Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98:15149, 2001.
214. van de Vijver MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999, 2002.
215. Wulfkuhle JD, et al: Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 532:59, 2003